Member Profile

Formosa Pharma (6838) was founded in 2010 as a biopharmaceutical company focusing on drug development in clinical-stage ophthalmology and oncology fields. Formosa Pharma possesses a broad application and comprehensive patent protection for its APNT® nanoparticle formulation platform and new drug assets. Its flagship drug, APP13007, targeting treatment of post-operative ocular inflammation and pain, received FDA approval in March 2024 and has been licensed in Greater China, the United States, Brazil, and the Middle East- North Africa region.

The APNT® platform technology helps improve drug dissolution performance, enhance bioavailability, and stabilize formulations, thereby facilitating successful formulation development.

Another key project is the antibody-drug conjugate TSY-0110, referencing Roche’s Kadcyla, one of the leading ADC drugs for treating HER2-positive breast cancer with a global market size of approximately $2 billion. The development of biosimilar drugs involves significant technological barriers, and Formosa Pharma is collaborating with Eirgenix Biotechnology to develop TSY-0110 using high-quality antibodies as the main raw material combined with Formosa Laboratories’ bioconjugation technology and high-activity formulation production capabilities. The project is poised to enter Phase I clinical trials in EU in near future.